Once again, the MET-targeted anticancer drug Tabrecta is attempting to receive insurance reimbursement in Korea.

According to industry sources, Novartis Korea has recently started the reimbursement process for Tabrecta (capmatinib in Korea. As the agenda was unable to pass deliberation by the Health Insurance Review and Assessment Service’s Cancer Disease Drug Committee deliberations in August, whether the company will succeed in its second attempt for reimbursement remains to be seen.


MET mutation is a rare type of cancer that is present in approximately 3-4% of patients with non small-cell lung cancer (NSCLC). No treatment option had been available in the type until now.